Your browser doesn't support javascript.
loading
HER2-low expression in patients with advanced or metastatic solid tumors.
Uzunparmak, B; Haymaker, C; Raso, G; Masciari, S; Wang, L; Lin, H; Gorur, A; Kirby, B; Cimo, A-M; Kennon, A; Ding, Q; Urschel, G; Yuan, Y; Feng, G; Rizvi, Y; Hussain, A; Zhu, C; Kim, P; Abbadessa, G; Subbiah, V; Yap, T A; Rodon, J; Piha-Paul, S A; Meric-Bernstam, F; Dumbrava, E E.
Afiliación
  • Uzunparmak B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Haymaker C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Raso G; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Masciari S; Department of Sanofi, The University of Texas MD Anderson Cancer Center, Cambridge, USA.
  • Wang L; Department of Sanofi, The University of Texas MD Anderson Cancer Center, Cambridge, USA.
  • Lin H; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Gorur A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Kirby B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Cimo AM; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Kennon A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Ding Q; Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Urschel G; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Yuan Y; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Feng G; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Rizvi Y; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Hussain A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Zhu C; Department of Sanofi, The University of Texas MD Anderson Cancer Center, Cambridge, USA.
  • Kim P; Department of Sanofi, The University of Texas MD Anderson Cancer Center, Cambridge, USA.
  • Abbadessa G; Department of Sanofi, The University of Texas MD Anderson Cancer Center, Cambridge, USA.
  • Subbiah V; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Yap TA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of The Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Khalifa Institute for Personalized Cancer Therapy
  • Rodon J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Genomic Medicine, The University of Texa
  • Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Surgical Oncology, The University of Tex
  • Dumbrava EE; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: eeileana@mdanderson.org.
Ann Oncol ; 34(11): 1035-1046, 2023 11.
Article en En | MEDLINE | ID: mdl-37619847
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Neoplasias Primarias Secundarias Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Neoplasias Primarias Secundarias Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Año: 2023 Tipo del documento: Article